Valneva plunges then recovers: what's really happening with the stock and the VLA2001 vaccine?
If you've been following this French biotech for the past decade, you know that roller-coaster rides are par for the course. But what happened to Valneva this week would make even the most seasoned investors wince. The stock abruptly broke below €4.35, flirting with €3.89 before showing some signs of a rebound. A shake-up like this always sets alarm bells ringing for retail investors. So, what's behind this latest about-face?
Solid financial results, but a fickle market mood
To put things in context, the financial results released a few days ago show the company is on solid ground. Revenue is there, cash flow is stable, and the development of vaccine candidates is progressing. So why the drop? Because in the stock market, especially for a company of this size, the devil is in the expectations. The market was likely expecting a more aggressive outlook or more blockbuster announcements regarding the progress of its famous Lyme disease vaccine.
But here, we're talking about science, not magic. Thomas Lingelbach, the CEO, says it every time he speaks: developing preventative vaccines against infectious diseases doesn't happen overnight. VLA15 (the name of their Lyme disease candidate) is probably the most closely watched program in the industry because if it succeeds, it will be the first modern-day "golden goose" against this disease. But until the final green light is given, the share price remains under pressure.
VLA2001, the COVID vaccine that changed the game... and expectations
Let's not forget where we've come from. With VLA2001, Valneva proved it could play with the big boys. This inactivated virus vaccine, used particularly within strict protocols, was a real breath of fresh air. For those following the regulatory side of things, the Generic Protocol for ECDC Studies of COVID-19 Vaccine Effectiveness Against Confirmed SARS-CoV-2 Using Healthcare Worker Cohorts: Version 3.0 remains an important benchmark for evaluating real-world effectiveness.
But today, the market has a short memory. The COVID era is behind us, and investors don't want to hear about legacy vaccines anymore. They want something new, something disruptive. Right now, Valneva finds itself in a bit of a lull, caught between the end of the COVID euphoria and the still-ongoing maturation of its Lyme pipeline. This is often the period where share prices suffer the most because traders hate a vacuum. They prefer blockbuster quarterly announcements over quiet waiting periods.
Reasons to be optimistic (or not) for the future
So, what should you do if you have Valneva in your portfolio or are eyeing the stock with interest? Here are a few key points worth considering:
- Cash and visibility: The company has secured funding and partnerships. It's not going anywhere anytime soon. The financial results confirm this: they have the means to stay the course until the next major milestones.
- The Lyme timeline: VLA15 is the main catalyst. The next data readouts, if positive, could literally send the stock soaring. It's a binary situation, but with enormous potential.
- Thomas Lingelbach's experience: He's no novice. He's weathered far bigger storms than this minor market chill. His strategy, focused on developing preventative vaccines, remains consistent.
In the stock market, emotions are often amplified with this type of stock. The drop below €4.35 triggered stops and automatic selling, which mechanically amplified the move. It's classic. What's more interesting is to see if the stock can stabilise above this psychological threshold in the coming sessions. If it does, the technical rebound could be just as brutal as the fall.
Let's not kid ourselves, betting on Valneva today is betting on the biotech of tomorrow, with all the risks and rewards that entails. But those who held on during the uncertain phases with VLA2001 will remember: when the science delivers, the market always catches up in the end.